PellePharm: PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome

Trial rapidly enrolled in 8 months Trial size expanded to accommodate 24 more patients than plannedPellePharm Inc. a BridgeBio Pharma Inc. Nasdaq BBIO company today announced the completion of enrollment for its pivotal Phase 3 clinical trial of Patidegib...